Apr 19, 2010
SuppreMol Receives U.S. Orphan Drug Designation for SM101

Apr 12, 2010
SuppreMol initiates Phase Ib/IIa clinical trial with its lead candidate SM101

Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

September 15-17, 2010
BioPharma America 2010, Boston, MA, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol GmbH is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

At present, SuppreMol develops drug candidates for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis and Psoriasis. Its lead product SM101 already is in clinical development.

The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry and is located in Martinsried near Munich, Germany.